NCT05631990CompletedPhase 2
A Study to Evaluate the Efficacy and Safety of AD-209
A Randomized, Double-Blind, Parallel, Multi-Center, Phase 2 Clinical Trial to Evaluate the Efficacy and Safety of AD-209 in Patients With Essential Hypertension
Source: ClinicalTrials.gov · Last updated 5 Apr 2024
Brief summary (registry, in English)
The purpose of this study is to evaluate the efficacy and safety of AD-209
- Status (registry)
- Completed
- Phase (registry)
- Phase 2
- Study type
- Interventional
- Enrollment
- 221 (actual)
- First submitted
- 20 Nov 2022
- Start date
- 5 Apr 2023
- Primary completion date
- 27 Nov 2023
- Lead sponsor
- Addpharma Inc.
- Diseases
- High blood pressure
- NCT number
- NCT05631990
What you commit to
- Study type: Interventional · Phase 2
- Participants enrolled: 221
- From 5 Apr 2023 to the primary completion date, 27 Nov 2023
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other
- orthostatic hypotension with symptom
- Other exclusions applied
Who the study is looking for
- Signed informed consent
- Other inclusions applied
Age in the registry: 19 years to 74 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Korea University Guro Hospital Coordinator of this site? Confirm its status | Seoul | South Korea | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.